Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Impact · against what's priced in

Immatics shares are likely to rise following positive Phase 1 data for IMA203CD8, which demonstrated meaningful clinical activity and manageable safety in hard-to-treat gynecologic cancers and synovial sarcoma. The ability to show efficacy in ovarian cancer, despite lower PRAME expression levels, suggests a broader therapeutic application across various solid tumors.

IMTX+0.70

No priced-in read yet